Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.32 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 2/20 | 0.32 |
| ▸ | CNR2 | P34972 | 2/20 | 0.32 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.32 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.32 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.32 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22353788 | 0.84 | MTNR1A (0.38) | L3MBTL1MTNR1AMTNR1BCNR1CNR2 | |
| SCHEMBL24259317 | 0.79 | CNR2 (0.34) | CNR1CNR2SIRT2 | |
| SCHEMBL24259059 | 0.78 | NR1H4 (0.36) | CNR1CNR2 | |
| SCHEMBL22352695 | 0.77 | POLB (0.43) | L3MBTL1MTNR1AMTNR1BCNR2LMNA | |
| SCHEMBL22353628 | 0.77 | ITGB3 (0.35) | L3MBTL1MTNR1AMTNR1BCNR1CNR2 | |
| SCHEMBL24258755 | 0.74 | NR1H4 (0.39) | L3MBTL1MTNR1AMTNR1BLMNA | |
| SCHEMBL24259058 | 0.73 | HDAC1 (0.40) | L3MBTL1MTNR1AMTNR1BLMNAMEN1 | |
| SCHEMBL24259248 | 0.73 | ALOX5AP (0.35) | L3MBTL1MTNR1AMTNR1BCNR1CNR2 | |
| SCHEMBL24452455 | 0.71 | MTNR1A (0.50) | MTNR1AMTNR1BMEN1KMT2A | |
| SCHEMBL24451785 | 0.71 | MTNR1A (0.35) | L3MBTL1MTNR1AMTNR1BCNR2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11713312-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-01 | — | — | US | disclosed |
| US-20220135550-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-05-05 | — | — | US | disclosed |
| US-11254663-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135550-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | FXR1, NR1H4, FXR2 | L3MBTL1 4270/4885MTNR1A 555/4885MTNR1B 679/4885 |
| US-11254663-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | FXR1, NR1H4, FXR2 | L3MBTL1 4270/4885MTNR1A 555/4885MTNR1B 679/4885 |
| US-11713312-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | FXR1, NR1H4, FXR2 | L3MBTL1 4270/4885MTNR1A 555/4885MTNR1B 679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.